Lauren J. Sullivan

Lauren J. Sullivan

Auto-generated profile, based on publicly available information

Lauren J. Sullivan

Medical University of South Carolina, Charleston, SC, United States

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in Chest
Verified
Journal Article
Open access
W. Cameron McGuireW. Cameron McGuire
W. Cameron McGuire
LSLauren Sullivan
Lauren Sullivan
MOMazen F. Odish
Mazen F. Odish
BDBrinda Desai
Brinda Desai
TMTimothy A. Morris
Timothy A. Morris
TFTimothy M. Fernandes
Timothy M. Fernandes
Acute pulmonary embolism (PE) is a common disease encountered by pulmonologists, cardiologists, and critical care physicians throughout the world. For patients with high risk (defined by systemic hypotension) and intermediate high-risk (defined by the absence of systemic hypotension but the presence of numerous other concerning clinical and imaging features) acute PE, intensive care is often necessary. Initial management strategies should focus on optimization of right ventricular (RV) function while decisions about advanced interventions are being considered. Here we review the existing literature of various vasoactive agents, intravenous fluids and diuretics, and pulmonary vasodilators in both animal models and human trials of acute PE. We also review the potential complications of endotracheal intubation and positive pressure ventilation in acute PE. Finally, we review the data of veno-arterial extracorporeal membrane oxygen use in acute PE. The above interventions are discussed in the context of the underlying pathophysiology of acute RV failure in acute PE with corresponding illustrations. Norepinephrine is a reasonable first choice for hemodynamic support with vasopressin as an adjunct. Intravenous loop diuretics may be useful if there is evidence of RV dysfunction or volume overload. Fluids should only be given if there is concern for hypovolemia and absence of RV dilatation. Supplemental oxygen administration should be considered even without hypoxemia. Positive pressure ventilation should be avoided if possible. VA-ECMO cannulation should be implemented early if ongoing deterioration occurs despite these interventions.

24 April 2025 in Drugs & Aging
Verified
Journal Article
Open access
PDF file
LSLauren J. Sullivan
Lauren J. Sullivan
CMChristina M. Mingora
Christina M. Mingora
PFPatrick A. Flume
Patrick A. Flume
Cystic fibrosis (CF) is an inherited condition that leads to multiorgan dysfunction, especially in the respiratory, gastrointestinal, and reproductive tracts, with associated conditions including persistent pulmonary infection, liver disease, pancreatic insufficiency, and infertility. Historically, people with CF (pwCF) suffered a shortened lifespan due to complications of the condition, namely respiratory. The emphasis on center-based, multidisciplinary care and the widespread introduction of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy has resulted in pwCF living longer and healthier lives. Now they may encounter some of the health and social issues associated with growing older, which previously were not a typical experience for this population. In this article, we review relevant health issues for the aging CF population, including complications that arise from the condition itself, issues encountered due to treatment, and general conditions associated with aging that may manifest earlier or differently in pwCF. We discuss the recommendations for screening and treatment of relevant conditions, and considerations for the integration of healthcare professionals across disciplines into the care of this population.

2 September 2025 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
LSLauren J. Sullivan
Lauren J. Sullivan
PFPatrick A. Flume
Patrick A. Flume